From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control
- PMID: 18671874
- PMCID: PMC2527562
- DOI: 10.1186/1472-6963-8-165
From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control
Abstract
Background: Achieving the Millennium Development Goals for health requires a massive scaling-up of interventions in Sub Saharan Africa. Intermittent Preventive Treatment in infants (IPTi) is a promising new tool for malaria control. Although efficacy information is available for many interventions, there is a dearth of data on the resources required for scaling up of health interventions.
Method: We worked in partnership with the Ministry of Health and Social Welfare (MoHSW) to develop an IPTi strategy that could be implemented and managed by routine health services. We tracked health system and other costs of (1) developing the strategy and (2) maintaining routine implementation of the strategy in five districts in southern Tanzania. Financial costs were extracted and summarized from a costing template and semi-structured interviews were conducted with key informants to record time and resources spent on IPTi activities.
Results: The estimated financial cost to start-up and run IPTi in the whole of Tanzania in 2005 was US$1,486,284. Start-up costs of US$36,363 were incurred at the national level, mainly on the development of Behaviour Change Communication (BCC) materials, stakeholders' meetings and other consultations. The annual running cost at national level for intervention management and monitoring and drug purchase was estimated at US$459,096. Start-up costs at the district level were US$7,885 per district, mainly expenditure on training. Annual running costs were US$170 per district, mainly for printing of BCC materials. There was no incremental financial expenditure needed to deliver the intervention in health facilities as supplies were delivered alongside routine vaccinations and available health workers performed the activities without working overtime. The economic cost was estimated at 23 US cents per IPTi dose delivered.
Conclusion: The costs presented here show the order of magnitude of expenditures needed to initiate and to implement IPTi at national scale in settings with high Expanded Programme on Immunization (EPI) coverage. The IPTi intervention appears to be affordable even within the budget constraints of Ministries of Health of most sub-Saharan African countries.
Similar articles
-
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.PLoS One. 2010 Jun 15;5(6):e10313. doi: 10.1371/journal.pone.0010313. PLoS One. 2010. PMID: 20559558 Free PMC article.
-
Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial.BMC Public Health. 2011 Jul 18;11:573. doi: 10.1186/1471-2458-11-573. BMC Public Health. 2011. PMID: 21767403 Free PMC article. Clinical Trial.
-
Development of behaviour change communication strategy for a vaccination-linked malaria control tool in southern Tanzania.Malar J. 2008 Sep 29;7:191. doi: 10.1186/1475-2875-7-191. Malar J. 2008. PMID: 18823531 Free PMC article.
-
Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.Lancet. 2009 Oct 31;374(9700):1533-42. doi: 10.1016/S0140-6736(09)61258-7. Epub 2009 Sep 16. Lancet. 2009. PMID: 19765816 Review.
-
Intermittent preventive therapy for malaria: progress and future directions.Curr Opin Infect Dis. 2007 Dec;20(6):613-20. doi: 10.1097/QCO.0b013e3282f1ae3b. Curr Opin Infect Dis. 2007. PMID: 17975412 Review.
Cited by
-
Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.Am J Trop Med Hyg. 2022 Aug 22;107(4):796-803. doi: 10.4269/ajtmh.21-1218. Print 2022 Oct 12. Am J Trop Med Hyg. 2022. PMID: 35995135 Free PMC article. Clinical Trial.
-
Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strategies in Jasikan, Ghana.PLoS One. 2011;6(11):e24871. doi: 10.1371/journal.pone.0024871. Epub 2011 Nov 3. PLoS One. 2011. PMID: 22073137 Free PMC article. Clinical Trial.
-
Making the most of malaria chemoprevention.Malar J. 2024 Feb 19;23(1):51. doi: 10.1186/s12936-024-04867-5. Malar J. 2024. PMID: 38369497 Free PMC article. Review.
-
Cost-effectiveness of intermittent preventive treatment of malaria in pregnancy in southern Mozambique.PLoS One. 2010 Oct 15;5(10):e13407. doi: 10.1371/journal.pone.0013407. PLoS One. 2010. PMID: 20976217 Free PMC article. Clinical Trial.
-
Human resources for health care delivery in Tanzania: a multifaceted problem.Hum Resour Health. 2012 Feb 22;10:3. doi: 10.1186/1478-4491-10-3. Hum Resour Health. 2012. PMID: 22357353 Free PMC article.
References
-
- United Nations Statistics Division The Millenium Development Goals Report. New York. 2006.
-
- Hutubessy RC, Baltussen RM, Torres-Edejer TT, Evans DB. Generalised cost-effectiveness analysis: an aid to decision making in health. Appl Health Econ Health Policy. 2002;1:89–95. - PubMed
-
- Hutton G, Tediosi F. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg. 2006;75:119–130. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical